outlook hype potenti healthcar transform
refresh two-stag valuat model boost confid target
price reiter outperform rate top-pick ew
despit commerci cycl continu initi neutral
outperform neutral
reiter outperform rate dinner co-found
outlook healthcar provid specialti name coverag
strateg updat add option pipelin
anoth piec pdh/pp puzzl
rais target price reiter outperform sop show
year ahead outlook top question head
regain competit foot innov driver
reiter outperform rais target price
suppli devic outlook new decad
year ahead outlook top idea lh chwi
rais target price manag track exceed
track higher organ growth rais target price
anoth guid cut weak price outlook leav question credibl
need re-built back project execut
posit data view pnh commerci opportun remain
public contain summari recent credit suiss research report bring notabl research attent full report summari
certif legal entiti disclosur inform statu non-u analyst equiti research disclosur click
outlook hype
note discuss trend believ like drive digit health growth healthcar
innov updat unconvent player enter expand healthcar
earn outlook expect hcit cover name key takeaway
survey investor industri stakehold expect around variou develop
digit health healthcar head video
sever theme one goal make healthcar access afford
saw signific progress sever digit health area primari goal make
healthcar either access afford industri continu shift away
cure diseas short term focus popul toward diseas
prevent overal well-b lt focu total popul head key
trend like drive digit health growth includ acceler employ activist virtual
care ai adopt continu focu social determin primari care reinvent need
address trillion wast healthcar system etc
survey suggest industri stakehold investor bullish care/
institut investor expect around variou develop digit health hcit
head virtual data analyt top two technolog investor
excit industri stakehold pick virtual ai/machin learn
applic blockchain augment reality/virtu realiti technolog investor
industri stakehold least excit final group see slow transit
ff value-bas lack reimburs clariti biggest hurdl
adoption/awar digit health/hc innov
outlook expect cover name believ expect
strong beat benefit continu growth
recent invest increas on-line order fulfil etc benefit full
quarter benefit contract above-averag flu season expect
rel modest respect outlook see
ehth revenue growth guidanc exceed con growth expect though survey
indic buy-sid expect closer see organ revenue growth
guidanc con also expect issu guidanc
particular see guidanc come ahead con primarili driven accent acq
close late dec reflect con
review model head earn reinstat coverag follow
recent close acquisit accent specif rais revenu ebitda
ep estim mln mln respect also updat
model reflect gradual improv ebitda margin previous expect
beyond specif ebitda estim mln vs mln
previous ep estim vs prev revenu estim remain
unchang mln
date product utc date dissemin utc
initi neutral
outperform neutral
view commerci mreit rel fairli valu part cycl given comfort
near-term outlook commerci real estat credit qualiti expect allow
sector continu gener high-single/low double-digit roe dividend yield current
valuat see major total return come dividend
initi apollo commerci estat financ neutral rate
price initi coverag neutral rate target price
target price deriv use multipl current book valu peer roe/
price book regress given weaker credit qualiti histori peer potenti spread
compress matur in-plac loan potenti dividend cut
initi neutral rate target
price initi coverag neutral rate target price
target price deriv use multipl current book valu lowest target
multipl commerci mreit coverag given expect lowest expect roe
sector see risk dividend first quarter like keep
lid valuat
upgrad downgrad remain top pick upgrad
outperform neutral increas target price repres
price-to-book upgrad base increas confid around abil rais capit
improv oper scale/return potenti dividend increas given coverag
level downgrad neutral outperform maintain
target price current valuat price-to-book see limit total return potenti
come year downgrad sole base valuat continu see stabil
bxmt roe best-in-class credit qualiti perform remind remain
commerci estat cycl remain cautious optimist comfort
underli health commerci real estat cycl despit extend natur current
real estat cycl full look view commerci landscap see latest
commerci estat tracker note
valuat given continu low level yield commerci mreit current
trade bp spread bbb- yield high saw earlier year
compar bp averag spread past five year given low absolut level
rate unsurpris spread wide level act somewhat
cushion rate rise
risk biggest risk commerci mortgag reit rate target price continu
broad econom turndown well weaken underwrit trend oversuppli new
build could result decreas book valu increas reserv earn
date product utc date dissemin utc
outlook healthcar provid
specialti name coverag
rate outperform go compani
challeng come implement home health medicar reimburs chang
well less signific rehab hospit reimburs chang began octob
home health industri receiv relief final rule octob
estim flat slight ebitda growth believ could
outperform base estim compani work reimburs issu
past manag strong track record execut reimburs chang hit
small player industri even harder provid increment organ growth acquisit
md rate md share outperform go compani trade around
ebitda low end histor rang due soft financi perform
post last two year howev expect begin show sign
stabil md intern initi improv oper perform take hold
addit compani begin redeploy capit toward acquisit fact
md announc sizeabl radiolog deal earli januari previou convers
manag md suggest acquisit spend could least mln vs less
mln sale meddata produc opportun pay debt complet
acquisit repurchas share final three investor involv md
activist histori wall street journal report one starboard push sale
part compani think lbo possibl rang altern
compani option respect divest under-perform anesthesia busi
acadia healthcar remain neutral see interest
stori watch compani stumbl uk result labor challeng
currenc weak associ brexit issu appear stabil
us compani continu see strong demand solid organ growth manag
talk high-singl digit revenu growth ebitda margin improv
would upsid estim howev stock trade compani go
process sell uk busi remain unclear whether get
suffici price busi rel alreadi built stock price addit
prospect us remain attract compani stumbl five largest
domest facil optimist hope short-term oper issu
back track mid-year
name provid specialti coverag also rate
outperform remain neutral
updat target price estim updat target price estim
also updat estim
outlook hospit industri see separ note outlook
expect solid financi result polit nois continu
date product utc date dissemin utc
price month
rais target price reiter
expect strong underli growth drive solid perform see
perform driven on-going excelsiusgp placement implant pull-through well strong
 spine growth share gain recal compani deliv unexpect upsid
robot sale continu above-market growth spine repres success pull-
thru implant util compani grow instal base excelsiusgp robot
surgeri system new product launch includ addit applic robot surgeri
platform interbodi cranial navig also expect key driver
see acceler reiter outperform rate rais target
model bp ebitda margin acceler ebitda margin
bp cse sequenti adjust ebitda
margin still expect slightli year-over-year due invest
distribut invest robot surgeri new imag platform trauma manag
remain track end year rang in-lin full-year guidanc
forecast bp ebitda expans expect manag continu invest
imag navig robot
back new price sop analysi use sop analysi get
deriv equiti valu per share repres impli ev/ebitda multipl
ebitda estim mil target multipl two-turn discount
sop-deriv ev/ebitda multipl suggest target multipl
reason potenti conserv
valuat target price base target multipl previous
project ebitda mil previous mil target multipl half turn
current multipl ntm ebitda reflect manag execut strength
base busi pull-through excelsiusgp risk product delay quarterli variabl
robot system sale unexpect surgic volum declin potenti new litig regulatory/
date product utc date dissemin utc
head
head remain bullish mco expect core oper earn
mco high singl low doubl digit rang compar basi upsid possibl
commerci medic cost trend better built current estim see
capit deploy ad low-to-mid singl digit earn growth take compar all-in
ep growth exclud hif low mid-teen percentag rang
mco rerat posit despit nois experienc sever point
last year mco ex-wcg involv deal ex-cv averag
rang ntm price-to-earnings basi mco end
year trade ex-wcg rang
compar earli octob mco trade ci
year background manag care impact sever factor
includ part safe harbor rebat propos court case sell-sid hospit survey
suggest volum increas y/i poll variou time year show
propon berni sander elizabeth warren gain ground race
democrat presidenti nomine formal releas elizabeth warren medicare-for-al
plan iron effect make mani financi market see
disrupt meaning prospect passag
medic trend enrol expect expect medic cost trend
steadi favor mco anticip stabl modest pickup medic cost
respect enrol government trend continu strong driven commerci enrol
exclud public exchang steadi modestli yti respect hix see
enrol declin modestli indic recent government data howev see
enrol gain driven market expans ci expand new hix market ad plan
kansa utah go also move market florida bring
compani presenc total market state well new counti
tennesse virginia
thought top investor question head note highlight top
investor question along thought mco head
focu name also offer strong return potenti
offer strong visibl target annual ep growth next sever
year stand benefit attract growth dynam medicar advantag
seen recession-resist play among mco
rais target price updat ep given hif repeal
repeal hif repres earn upsid mco coverag rais
tp addit roll forward year tp multipl
wcg
date product utc date dissemin utc
driver reiter
outperform rais target price
continu improv growth share gain falter late last year rais
doubt compani abil hold ground competit robot spine surgeri
system regain competit foot deliv three quarter improv us
spinal hardwar growth culmin growth market grow
signific improv improv growth attribut
best launch new innov product enabl technolog well-
design procedur instrument implant help minim invas spine surgeon
achiev better outcom reproduc effici way see increas adopt
later single-posit procedur well pull-through posterior fixat technolog
drive growth go forward xlif surgeon train see ampl
runway ahead reiter outperform rate rais target
earli interest puls encourag manag continu control roll-out
integr plan navig system puls see potenti share gain
beyond launch robot surgeri applic expect meet
exceed competitor featur capabl nuva leadership faster-grow mi
spine segment key innov product cycl posit compani drive continu
share gain next year
innov focus three major area nuva key focu area includ robot
enabl technolog drive adopt minim invas surgeri cervic deform
segment global scale expect compani activ invest intern
strateg support continu above-market growth sharehold valu
valuat target price base ebitda multipl previous
adjust ebitda mil previous ntm adjust ebitda mil
target multipl roughli line nuva current multipl risk competit
robot surgeri product delay failur progress long-term goal litig regulatory/
date product utc date dissemin utc
price month
lh chwi
continu view less convent name attract play healthcar particularli
head us presidenti elect year healthcar access drug price remain key
topic debat drive heighten headlin risk volatil associ name includ drug
distributor context favor anim health sector inher shield tradit
human health dynam underli fundament remain robust healthi pet adopt
human pet market-expand innov embrac new altern
channel also offer support dental focu renew innov effort
offer company-specif catalyst particularli relev still lacklust albeit seemingli stabil
north america end market meanwhil biotech fund level remain elev trend
shelter binari outcom inher drug develop lastli across current life
scienc diagnosticscohort favor compani diversifi platform
offer multipl lever growth summar best idea across broad coverag
univers head
dentaltop pickdentspli sirona manag demonstr build
traction turnaround stori aggress restructur plan step innov
meaning materi head view continu reap
reward initi beyond
anim health top pickchewi inc chwi leader pet e-commerc chwi well
posit amid robust pet care industri expand custom base uniqu custom
engag consider autoship adopt support strong recur revenu stream
line sight adj ebitda profit leverag technolog expand
product offer along ramp scale importantli make chang posit
bia zoetisa industri leader momentum continu innov catalyst
bolster alreadi immens diversifi global portfolio high visibl growth strong
contract research organ top pickia hold book
billion merger-to-d relat solut contribut meaning
top-line growth ahead industri recent unveil medium-term guidanc call
organ growth clearli set lofti lt growth goal view
leverag unmatch data asset size scale captur greater share also
life sciences/diagnost top picklabcorp lh view multipl avenu growth across
lh diversifi platform despit continu headwind core clinic laboratori servic
cro driver strong cash flow gener offer capit deploy flexibl particularli
relev given role lead consolid smaller lab oper post-pama world
adjust target price across specif compani variou factor includ regulatori
overhang demand dynam company-specif factor
date product utc date dissemin utc
rais target price
manag track exceed
improv organ growth support strong pipelin new product
remain track meet exceed organ growth guidanc driven improv
execut new product compani result organ growth de-risk
compani outlook take pressur creat potenti
upsid addit expect compani end solid head steam array
new recent launch product expect drive continu growth
reiter outperform rais target price
pipelin track drive beyond expect org growth
better in-lin manag guidanc acceler growth driven part
low-risk tavr launch approv next-gen evolut pro tavr
mazorx minim hybrid close loop system next-gen intelli
addit expect new product launch carri follow fiscal year
beyond posit meet exceed long-run growth target
incom ceo potenti catalyst impress geoff martha record
execut restor therapi group see appoint ceo end
opportun drive improv perform across compani busi line
well term background rtg growth rate improv end
mr martha tenur driven larg part new product launch
acquisit includ mazor robot surgeri system
valuat target price prev base ebitda multipl
ntm ebitda estim bil one year forward unch multipl
roughli line mdt current multipl risk product delay failur progress
long-term goal growth margin potenti new litig regulatori qualiti issu
date product utc date dissemin utc
price month
price month
track higher organ growth
rais target price
acceler organ growth remain manag goal deliv
organ growth vs cs estimate factset consensu narrow
organ growth guidanc expect management target higher growth vs
management yet provid formal guidanc expect compani end year
good momentum benefit throughout healthi array new product
catalyst reiter outperform rate rais target price
structur heart continu build momentum driven watchman lotu
neo bsx sh busi remain larg driven watchman avail
 account exceed treat patient despit still scratch
surfac term market penetr low singl digit lotu continu build
momentum quarter remain pace reach center april expect
enabl compani reach share us tavr acur launch
europ also help reinvigor ou tavr growth
exalt-d product watch compani plan commenc limit market releas
devic management see bil potenti market opportun
exalt-d although remain uncertainti pace growth price new
disrupt market segment demand strong market shift quickli think
mil estim could prove conserv see exalt-d potenti unknown
growth driver could drive upsid revis
categori get strong start
valuat target price previous base previous ebitda
multipl ebitda bil unchang target multipl in-lin current
multipl ntm ebitda reflect diversifi portfolio consist manag
execut invest product pipelin risk product delay failur progress lt
date product utc date dissemin utc
anoth guid cut weak price outlook
leav question credibl need
re-built back project execut
pre-announc w/ new rang bookend difficult year ahead offici
releas late februari revis guidanc yet reflect
extent difficult market condit compani face see revenu
rang vs adj ebitda vs
adj ep vs cut due lower realiz price push
margin even lower alreadi depress level still incur vat upon export
china well higher feedstock cost parti suppli also suffer delay
lioh order quarter remain seen mani order recoup
alreadi plan carri higher inventori per lg chem
suppli agreement adj ebitda est vs
tp drop risk expans execut guid credibl
harsh re-set expect headwind linger investor well awar
li market condit far construct nt subsidi volatil feedstock oversuppli
irrat market actor etc extent impli challeng like strike mani
surpris expect adj ebitda level vs con impli
growth back price declin low-mid teen yr/yr plan purchas
third parti li carbon support higher volum margin headwind cse
ebitda margin low-mid well-below high qualiti peer reiter
previous commun volum guidanc compound impact two
factor off-set associ benefit
await capit expans updat call stop short call stori
de-risk believ commentari expans plan far import lt thesi
result cse key pivot point lioh plant bessem citi
carbon project argentina well-underway expect potenti delay
manag understand project execut essenti build industri relev
management may take slightli cautiou stanc less will lean revolv given
shrink ebitda base neg free cash flow
date product utc date dissemin utc
price month
posit data view pnh
chang thesi today pegasu efficaci data came ahead investor
expect though doesnt meaning chang view commerci opportun
pnh believ clinic profil emerg trial support
may commerci nich opportun pnh pnh patient well control
inhibitor howev continu see broader uptak front-lin therapi rel
unlik given well-establish soliris/ultomiri sticki natur rare diseas market
dispers prescrib base us think potenti commerci opportun
pnh reflect current valuat consid unknown potenti launch
uncertainti actual commerci opportun pipelin program
investor dialogu focus approv think today pegasu data increment
de-risk pnh increas po program
question receiv focus approv base
dataset present think total data gener pegasu trial like
seen favor regul overli concern languag
rise hemoglobin level may translat clinic benefit patient enter
trial high hemoglobin level permit inclus criteria pegasu trial
requir transfus would like seen data broken
transfus depend baselin compani indic detail data eha baselin hb
level suggest sub-optim control popul result transfus avoid
suggest potenti benefit beyond increas hb
model updat increas po take tp
risk thesi clinic regulatori commerci potenti financ
date product utc date dissemin utc
confid target price reiter
outperform rate top-pick ew
ew remain high convict top pick signific potenti upsid weve updat
differenti two-stag valuat model ew support potenti upsid ew
next month boost confid target price
target price reflect potenti upsid current level valuat
scenario impli potenti upsid updat valuat analysi support view
stock reach exceed target price next month potenti reach
scenario valu reiter outperform rate target
price expect ew continu substanti outperform univers market
differenti two-stag valuat approach suggest ew exceed
price two-stag valuat approach base ew yr rel ev/ebitda
multipl around twice multipl combin impact per share
bil increas consensu expect ww tavr market updat model
suggest support ew reach next month
target price line valuat scenario light
updat analysi view target reason conserv
management guidanc tavr leav open upper teen growth
compani tavr guidanc present ew recent analyst day highli anticip
close watch ww tavr outlook interpret slightli better
low double-digit commentari given earn call said note dollar
rang ww tavr guidanc present management bil actual suggest growth
high end rang report cc view updat
outlook posit came away year meet greater convict expect
continu strong growth us tavr market potenti drive addit upward revis
date product utc date dissemin utc
price month
reiter outperform rate dinner
tuesday even host investor dinner apollo co-found senior manag
director josh harri apollo remain highest convict outperform across asset manag
broker coverag reiter target price outperform rate
apo strong fre/aum growth trajectori mostli driven insur busi
market expect fund viii realiz perform fee low estim
transact octob help address largest perceiv risk stock
transact address sourc buysid pushback
despit total return apo stock still trade attract rel valuat
especi sum-of-the-part analysi
see key catalyst next larg insur acquisit athora
quarterli earn upsid potenti perform fee fre also
continu believ apo improv valuat long-onli sharehold base move
small amount vote right float would qualifi stock russel
import benchmark larg cap pm addit think apo could eventu migrat
fix dividend match fre remov risk downsid volatil present
perform fee also could help apo retain excess capit opportunist buyback
date product utc date dissemin utc
price month
strateg updat add option
doubl etrasimod gastro/derm indic expand immune/neuro
indic etrasimod eosinophil esophag eoe alopecia areata aa call
manag express confid target eoe base implic signal
key cytokines/cel type involv immune-medi inflammatori respons central diseas
patholog compani plan initi robust pbo-control dose-find studi
intend support singl pivot studi also appli orphan statu
indic aa manag see rational etrasimod base demonstr
modul activ dermatolog indic compani plan initi single-dos
proof-of-concept pbo-control studi aa beyond etrasimod manag
announc expand relationship beacon discoveri discovery/develop
protein coupl receptor gpcr agent immun inflammatori indic
format new subsidiari focus neuro indic specif target microgli
neuroinflamm final manag announc initi etrasimod cd program
dose first subject dhf trial
addit option increment posit rais etrasimod ceil modest
management remain confid etrasimod ibd see strategic/pipelin updat
increment posit indic continu manag confid lead agent etrasimod
ad option pipelin management highlight readout
one new ind per year next year importantli manag project newli
announc clinical/pre-clin effort nomin effect nt cash burn etrasimod
ibd uc crohn timelin remain track uc data expect late expect
investor focu shift read-through competitor agent bmi ozanimod near-
term ozanimod ms pdufa march uc data expect mid-year ahead
clinic catalyst back half year olorinab ib pain etrasimod atop derm
data expect
date product utc date dissemin utc
price month
price month
anoth piec pdh/pp puzzl
petrochem progress pembina pipelin corpor petrochem
industri compani pic kuwait announc canada kuwait petrochem
corpor ckpc execut lump sum engin procur construct
contract plan propan dehydrogen pdh facil part broader
pdh/pp pp polypropylen complex revis proportion pdh/pp capit
includ directli own support facil figur look
compar prior estim ckpc expect pdh/pp facil place
servic versu past new data may move closer
time block sold kinder morgan inc discuss past work
includ end annual investor day await block sale
select detail notabl includ contract roughli cost
pdh/pp facil fix increas cost associ pdh facil
fix lump sum contract ppl capit budget impact
chang kinder come close updat ckpc select heartland canada
partner partnership kiewit contactor
pdh secur anticip adjust ebitda fee-bas
arrang project continu work move figur
 pp contactor select process continu
invest thesi midstream asset key wcsb play provid visibl near-term
growth along potenti ngl margin expans
valuat outperform rate target price obtain averag
three method price-to-earnings multipl ev/ebitda multipl cs estim
dividend yield risk tp includ commod price weak caus
date product utc date dissemin utc
new decad disrupt begin
head remain bullish ms expect top-pick ew
outperform market project ms organ growth expect
sustain organ growth help drive out-performance discuss key macro debat face
sector highlight pivot question compani
date product utc date dissemin utc
ahead upcom icr confer held januari orlando florida
provid relev industri theme pertin question present compani within
coverag univers recent announc complet
reinhart acquisit could updat guidanc deal perhap conjunct
pre-announc typic discuss gener industri busi trend
could year provid initi detail plan construct next guidanc updat
announc holiday sale result icr confer last year like
year confer
date product utc date dissemin utc
